Chromium Picolinate “Insulin Resistance” Qualified Health Claim Clears FDA
This article was originally published in The Tan Sheet
Executive Summary
FDA approved Nutrition 21's chromium picolinate qualified health claim for reduced risk of insulin resistance that can lead to type 2 diabetes, the firm stated Aug. 29
You may also be interested in...
Nutrition 21 Chromax Claims Should Reflect “Real World” Performance – NAD
Nutrition 21 should modify performance claims for its newly launched Chromax chromium picolinate product to "more closely mirror the results and limitations in the applicable studies," according to the National Advertising Division
Multiple Claims Slow Qualified Health Claims Petitions, Says Schneeman
Dietary supplement makers that submit multiple claims within a single qualified health claim petition may contribute to a delayed review period, CFSAN's Barbara Schneeman, PhD, stated at the Council for Responsible Nutrition annual conference
FDA Qualified Health Claims Process Needs Revising To Reduce Delays – CRN
FDA's "significant delays" in responding to qualified health claim petitions has prompted the Council for Responsible Nutrition to request that the agency review its claims process